ECSP961873A - CYCLE COMPOUNDS INHIBITORS OF ADHESION - Google Patents
CYCLE COMPOUNDS INHIBITORS OF ADHESIONInfo
- Publication number
- ECSP961873A ECSP961873A ECSP961873A ECSP961873A EC SP961873 A ECSP961873 A EC SP961873A EC SP961873 A ECSP961873 A EC SP961873A EC SP961873 A ECSP961873 A EC SP961873A
- Authority
- EC
- Ecuador
- Prior art keywords
- volumes
- lys
- phe
- amino acid
- hal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 102000001189 Cyclic Peptides Human genes 0.000 abstract 1
- 108010069514 Cyclic Peptides Proteins 0.000 abstract 1
- DTERQYGMUDWYAZ-UHFFFAOYSA-N N-acetyl-N-thioacetyl-Lysine Natural products CC(=O)NCCCCC(N)C(O)=O DTERQYGMUDWYAZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 125000003435 aroyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a nuevos ciclopéptidos de fórmula ciclo -(nArg-nGly - nAsp - nD- nE), en la que D y E independientemente representan Gly, Ala, Bala, Asn, Asp, Asp, (OR), Arg, Cha, Cys, Gln, Glu, His, Lle, Leu, Lys, Lys(Ac), Lys(AcNh2), Lys(AcSH), Met, Nal, Nle, Orn, Phe, 4-Hal, Phe, homo -Phe, Phg, Pro, Pya, Ser, Thr, Tia, Tic, Trp, Tyr, ó Val, pudiendo tratarse de derivados de estos amino ácidos; R representa alquilo de 1 a 18 tomos de C; Hal, F, Cl, Br ó L; Ac, alcanoilo de 1 a 10 tomos de C, aroilo de 7 a 11 tomos de C o arilalcanoilo de 8 a 12 tomos de C, y n significa que no hay sustituyentes o bien representa un resto de alquilo R, bencilo o un resto de arilalquilo de 7 a 18 tomos de C, unidos a la función alfa -amino del resto de amino ácido en cuestión; con la condición de que al menos uno de los restos de amino ácido presenta un sustituyente n, estndo incluidas tanto las formas D como las formas L en caso de uqe los amino ácidos y restos de amino ácidos tengan actividad óptica, y las sales inobjetables desde el punto de vista fisiológico de estos compuestos. Estos compuestos actúan como inhibidores de las integrinas y se pueden emplear en partcular para prevenir y tratar enfermedades del sistema circulatorio, enfermedades angiogénicas infecciones microbianas y para el tratamiento de tumores.The invention relates to novel cyclopeptides of the formula cyclo - (nArg-nGly-nAsp-nD-nE), in which D and E independently represent Gly, Ala, Bala, Asn, Asp, Asp, (OR), Arg, Cha , Cys, Gln, Glu, His, Lle, Leu, Lys, Lys (Ac), Lys (AcNh2), Lys (AcSH), Met, Nal, Nle, Orn, Phe, 4-Hal, Phe, homo -Phe, Phg, Pro, Pya, Ser, Thr, Tia, Tic, Trp, Tyr, or Val, being able to be derived from these amino acids; R represents alkyl of 1 to 18 volumes of C; Hal, F, Cl, Br or L; Ac, alkanoyl of 1 to 10 volumes of C, aroyl of 7 to 11 volumes of C or arylalkanoyl of 8 to 12 volumes of C, and n means that there are no substituents or represents an alkyl radical R, benzyl or an arylalkyl residue from 7 to 18 volumes of C, linked to the alpha-amino function of the amino acid residue in question; with the proviso that at least one of the amino acid residues has a substituent n, both D and L forms being included in case the amino acids and amino acid residues have optical activity, and the salts unobjectionable from the physiological point of view of these compounds. These compounds act as inhibitors of integrins and can be used in particular to prevent and treat diseases of the circulatory system, angiogenic diseases, microbial infections and for the treatment of tumors.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP961873 ECSP961873A (en) | 1996-09-12 | 1996-09-12 | CYCLE COMPOUNDS INHIBITORS OF ADHESION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP961873 ECSP961873A (en) | 1996-09-12 | 1996-09-12 | CYCLE COMPOUNDS INHIBITORS OF ADHESION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP961873A true ECSP961873A (en) | 1997-11-28 |
Family
ID=42042599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP961873 ECSP961873A (en) | 1996-09-12 | 1996-09-12 | CYCLE COMPOUNDS INHIBITORS OF ADHESION |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP961873A (en) |
-
1996
- 1996-09-12 EC ECSP961873 patent/ECSP961873A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR003574A1 (en) | CYCLIC COMPOUNDS, ADHESION INHIBITORS. | |
| NL300013I1 (en) | New protein with TNF-inhibiting effect and their ber | |
| EA200401471A1 (en) | APPLICATION OF CETR INHIBITORS AND POSSIBLE INHIBITORS OF HMG COA AND / OR ANTIHYPERTENSIVE AGENTS | |
| UA42747C2 (en) | PEPTIDE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD FOR STIMULATING GROWTH HORMONE SECRETION | |
| GR3036188T3 (en) | Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase | |
| CY1113202T1 (en) | Molecular Mimics of the Mining Peptide Peptides | |
| ATE219103T1 (en) | CNP ANALOGUE PEPTIDES AND THEIR USE | |
| PT883687E (en) | RECEPTORS OF CHIMIOCINES C-C, CKR-5, CC, THEIR DERIVATIVES AND THEIR USES | |
| WO1998033509A3 (en) | Useful properties of human lactoferrin and variants thereof | |
| DE69737990D1 (en) | NEW METABOTROPIC GLUTAMATE RECEPTOR FROM MAN | |
| DK0914144T3 (en) | Therapeutic uses of BPI protein products for human meningococcemia | |
| CY1109868T1 (en) | CD81 PROFESSIONAL SUBSCRIPTION PROTECTOR C | |
| ATE171712T1 (en) | NOVEL KUNITZ-TYPE HUMAN PROTEASE HIBITOR AND CORRESPONDING VARIANTS | |
| ES2054365T3 (en) | INHIBITION OF THE ROUTE OF THE FINAL N RULE IN LIVING CELLS. | |
| ATE202708T1 (en) | PEPTIDE ANTAGONISTS OF BRADYKININ | |
| IS2819B (en) | Vascular adhesion molecules and formulation of their activity @ | |
| PT863155E (en) | BLENDING OF T-CELL PROLIFERATION USING PEPTIDIC FRAGMENTS OF MYELINE BASIC PROTEIN | |
| ES2164902T3 (en) | FUNGICIDE BLENDS. | |
| ES2128348T3 (en) | OBTAINING COMPOSITIONS FOR THE TREATMENT OF ALTERATIONS OF CELL PROLIFERATION. | |
| NO941151L (en) | Linear adhesion inhibitors | |
| ECSP961873A (en) | CYCLE COMPOUNDS INHIBITORS OF ADHESION | |
| MXPA03001167A (en) | Stress proteins and peptides and methods of use thereof. | |
| KR0185973B1 (en) | Ghilanten, antimetastatic principle from the south american leech, haementeria ghilianii +b | |
| PE20010066A1 (en) | ACTIVATED PROTEIN C POLYPEPTIDE | |
| NO942360L (en) | Vaccine and polypeptides useful for this |